ANZGOG’s TAPER Study has received $1.27 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) which aims to improve the health and wellbeing of Australians by supporting medical research and innovation

Prof Alison Brand AM, Principal Investigator of TAPER.

ANZGOG to lead the trial in Australia and New Zealand

The funding for the study was announced by the Minister for Health and Aged Care, the Hon Mark Butler MP on 14, March 2023.

The international study is a multi-faceted collaboration between the Canadian Clinical Trials Group (CCTG) and ANZGOG which works towards improving patient outcomes and reducing the effects of this disease.

Under the leadership and guidance of Principal Investigator Professor Alison Brand AM, Gynaecological Oncologist and ANZGOG Director, ANZGOG will pioneer the trial in both Australia and New Zealand.

What is TAPER?

TAPER is a Phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer. The primary objective of the study is to estimate the rate of pelvic recurrence at three years in patients who are treated with a de-escalated adjuvant treatment directed by tumour molecular status.

Key eligibility criteria includes:

  • Patients must have had surgery consisting of hysterectomy (total abdominal, laparoscopic or robotic-assisted) and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards (sentinel or full lymphadenectomy) but must be done in grade 3 and Stage II. There must be no macroscopic residual disease after surgery.
  • Patients must have histologically confirmed Stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed
  • Patients’ Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2
  • Patients’ age must be over 18 years

Paving the way for a brighter future

The awarding of a $1.27 million grant for the TAPER study enables researchers to delve deeper into the molecular and genetic underpinnings of the disease while paving the way for ground-breaking discoveries that answer important questions for patients suffering from endometrial cancer. The TAPER study offers thousands of Australian women diagnosed with endometrial cancer every year hope for the future by devising effective ways of managing and treating the disease. #ImprovingLifeForWomen

Learn more about ANZGOG’s transformative trials and research.